Quadrant Capital Group LLC Purchases 54 Shares of argenx SE (NASDAQ:ARGX)

Quadrant Capital Group LLC grew its holdings in argenx SE (NASDAQ:ARGX) by 5.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,120 shares of the company’s stock after acquiring an additional 54 shares during the period. Quadrant Capital Group LLC’s holdings in argenx were worth $689,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Clearbridge Investments LLC boosted its position in shares of argenx by 6.8% during the fourth quarter. Clearbridge Investments LLC now owns 629,828 shares of the company’s stock worth $387,344,000 after acquiring an additional 40,330 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of argenx by 13.0% during the 3rd quarter. Wellington Management Group LLP now owns 482,346 shares of the company’s stock valued at $261,470,000 after purchasing an additional 55,617 shares during the last quarter. Jennison Associates LLC grew its position in shares of argenx by 27.0% during the fourth quarter. Jennison Associates LLC now owns 302,149 shares of the company’s stock valued at $185,821,000 after purchasing an additional 64,183 shares in the last quarter. Lord Abbett & CO. LLC bought a new stake in shares of argenx in the third quarter worth about $88,339,000. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of argenx by 38,152.3% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company’s stock worth $89,391,000 after buying an additional 143,834 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

argenx Stock Performance

NASDAQ:ARGX opened at $555.11 on Monday. The firm has a market cap of $33.73 billion, a P/E ratio of -630.81 and a beta of 0.60. The firm has a 50-day simple moving average of $621.43 and a 200-day simple moving average of $603.70. argenx SE has a one year low of $352.77 and a one year high of $678.21.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. On average, research analysts predict that argenx SE will post 3.13 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on ARGX. JMP Securities raised their price target on argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a report on Tuesday, January 14th. Piper Sandler boosted their price target on shares of argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 7th. William Blair reiterated an “outperform” rating on shares of argenx in a research report on Friday, February 28th. Truist Financial restated a “buy” rating and issued a $700.00 target price (up from $660.00) on shares of argenx in a report on Tuesday, January 14th. Finally, Robert W. Baird increased their price target on shares of argenx from $650.00 to $680.00 and gave the company a “neutral” rating in a report on Tuesday, March 4th. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, argenx has a consensus rating of “Moderate Buy” and an average price target of $687.00.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.